ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

COMBIVIR
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

COMBIVIR Rx

Generic Name and Formulations:
Lamivudine 150mg, zidovudine 300mg; scored tabs.

Company:
ViiV Healthcare

Therapeutic Use:

Indications for COMBIVIR:

HIV-1 infection, in combination with other antiretroviral agents.

Adults and Children:

<30kg: not recommended. ≥30kg: 1 tab twice daily. Hepatic or renal impairment (CrCl <50mL/min): not recommended; use individual components.

Warnings/Precautions:

Risk of hematologic toxicity/bone marrow suppression; monitor CBCs esp. in advanced HIV-1 disease; interrupt dose if anemia or neutropenia occurs. Myopathy with prolonged zidovudine use. Suspend if lactic acidosis or pronounced hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Not for treating chronic HBV infection; closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted. History of pancreatitis. Monitor for lipoatrophy; use alternatives if suspected. Women. Obesity. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

Avoid concomitant stavudine, doxorubicin, nucleoside analogues (eg, ribavirin), sorbitol-containing products. Increased hematologic toxicity with ganciclovir, interferon alpha, ribavirin, other bone marrow suppressants or cytotoxic drugs. Monitor for treatment-associated toxicities (eg, hepatic decompensation) with interferon-alpha with or without ribavirin.

Pharmacological Class:

Nucleoside analogues (reverse transcriptase inhibitors).

Adverse Reactions:

Headache, nausea, malaise, fatigue, nasal symptoms, diarrhea, cough; neutropenia, anemia, lactic acidosis, severe hepatomegaly with steatosis, myopathy, myositis, immune reconstitution syndrome, pancreatitis (discontinue if occurs), lipoatrophy.

Note:

Register pregnant patients exposed to lamivudine by calling (800) 258-4263.

How Supplied:

Tabs—60

Sign Up for Free e-Newsletters